Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.58 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13934145 | 0.82 | NPSR1 (0.46) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL13934148 | 0.80 | GLO1 (0.48) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL15273109 | 0.79 | GLO1 (0.77) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL1942274 | 0.79 | NPSR1 (0.62) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL13269051 | 0.79 | NPSR1 (0.62) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL4852525 | 0.78 | ALDH1A1 (0.53) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL15094234 | 0.78 | NPSR1 (0.56) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL3192124 | 0.78 | — | — | |
| SCHEMBL13973671 | 0.78 | — | — | |
| SCHEMBL3192121 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115850297-A | Synthetic method of sarin antibiotic drug intermediate | 常州兰陵制药有限公司 | 2023-03-28 | — | — | CN | claimed |
| CN-115819339-A | Synthesis method of 6, 7-difluoro-8-hydroxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid | 常州兰陵制药有限公司 | 2023-03-21 | — | — | CN | claimed |
| CN-115772176-A | Synthetic method of key drug intermediate of levofloxacin | 常州兰陵制药有限公司 | 2023-03-10 | — | — | CN | claimed |
| CN-115403521-A | Synthesis method of lomefloxacin hydrochloride intermediate | 常州兰陵制药有限公司 | 2022-11-29 | — | — | CN | claimed |
| CN-115819339-A | Synthesis method of 6, 7-difluoro-8-hydroxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid | 常州兰陵制药有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-115772176-A | Synthetic method of key drug intermediate of levofloxacin | 常州兰陵制药有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-115772176-A | Synthetic method of key drug intermediate of levofloxacin | 常州兰陵制药有限公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-115490606-A | Method for preparing medical intermediate from 2-chloromethylene-diethyl malonate | 安徽泽升科技有限公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-115403521-A | Synthesis method of lomefloxacin hydrochloride intermediate | 常州兰陵制药有限公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-115403521-A | Synthesis method of lomefloxacin hydrochloride intermediate | 常州兰陵制药有限公司 | 2022-11-29 | — | — | CN | disclosed |
| EP-1270577-B1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-12-06 | — | — | EP | disclosed |
| US-6924292-B2 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-02 | — | — | US | disclosed |
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | US | disclosed |
| EP-1270577-A1 | FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-01-02 | — | — | EP | disclosed |
| EP-0376870-A1 | A new organosilylpolyphosphoric reagent, its preparation and application to the process of synthesis of 3-carboxyquinolones or azaquinolones and their salts | CENTRO MARGA PARA LA INVESTIGACION S.A. (ES) | 1990-07-04 | — | — | EP | disclosed |
| EP-0168025-B1 | PROCESS FOR PRODUCING AMINOTHIAZOLYLPROPENDICARBOXYLIC ACID MONOESTERS | SHIONOGI & CO., LTD. (JP) | 1989-09-27 | — | — | EP | disclosed |
| US-4652652-A | PENICILLIN OR CEPHALOSPORIN INTERMEDIATE | SHIONOGI & CO., LTD. (JP) | 1987-03-24 | — | — | US | disclosed |
| EP-0168025-A1 | Process for producing aminothiazolylpropendicarboxylic acid monoesters | SHIONOGI & CO., LTD. (JP) | 1986-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092582-A1 | Furoisoquinoline derivatives, process for producing the same and use thereof | PDE3B, PDE5A, PDE3A | NPSR1 3231/4885GLO1 1389/4885ALDH1A1 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.